drugset
drugset / Trial / NCT01763021

A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants

NCT01763021 ↗

Phase 1 Completed 18 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the potential effects of rifampin on the pharmacokinetics (how the drug concentrations change over time) of PCI-32765 in healthy participants.

Timeline

Start
2012-12
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibrutinib Small molecule 560 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.